Athira Raveendran (전남대학교)

한빛사논문

조회38

Athira RaveendranAthira Raveendran

전남대학교

Adv. Sci., Sep 04 2024, | https://doi.org/10.1002/advs.202401424 Lysosome-Targeted Bifunctional Therapeutics Induce Autodynamic Cancer Therapy

Athira Raveendran ¹, Jinhui Ser ^1,2, Seung Hun Park ², Paul Jang ², Hak Soo Choi ², Hoonsung Cho¹

¹Department of Materials Science and Engineering, Chonnam National University, Gwangju, 61186, Republic of Korea.

²Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

A.R. and J.S. contributed equally to this work.

Corresponding Authors: Hak Soo Choi, Hoonsung Cho

Abstract

Autodynamic cancer therapy possesses tremendous potential for enhancing therapeutic efficacy by initiating the treatment process autonomously within targeted cells. However, challenges related to biocompatibility and targeted delivery have hindered its clinical translation owing to the induction of adverse effects and cytotoxicity in healthy cells. In this study, a novel approach for auto-initiated dynamic therapy by conjugating zwitterionic near-infrared fluorophores to a cell-penetrating peptide is proposed. This enables efficient cellular uptake and specific targeting of therapy to desired cells while avoiding off-target uptake. The zwitterionic bioconjugate causes cancer-specific toxicity following its internalization into the targeted cells, triggered by specific intracellular conditions in lysosomes. This innovative approach enables selective targeting of lysosomes in malignant cells while minimizing cytotoxic effects on normal cells. By targeting lysosomes, the method overcomes inherent risks and side effects associated with conventional cancer treatments, offering a selective and effective approach to cancer therapy.

논문정보

형식Research article
게재일2024년 09월 (BRIC 등록일 2024-09-11)
연구진국내(교신)+국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기